← Evidence map

ArticleGastro hep advances2026

Efficacy of Upadacitinib Retreatment or Dose Escalation After Loss of Response in Ulcerative Colitis: Data From the Open-Label Extension of the U-ACTIVATE Study.

Remo Panaccione et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

2 trials

NCT02819635phase 2/phase 31,302 enrolled2016 NCT03006068phase 3950 enrolled2017

Efficacy of Upadacitinib Retreatment or Dose Escalation After Loss of Response in Ulcerative Colitis: Data From the Open-Label Extension of the U-ACTIVATE Study. | OpenQuestion